AstraZeneca Purchases RSV Vaccine Developer In $1.1B Deal

Reuters (12/12, Shabong) reports, “AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.” Icosavax is said to be “developing a combination vaccine candidate targeting RSV and human metapneumovirus.”